Semaglutide and tirzepatide, a dual analogue of GLP-1 and glucose-dependent insulinotropic polypeptide (GIP), have recently been added to the pharmaceutical arsenal against T2DM. The gene discussed is GIP; the disease is type 2 diabetes mellitus.